Anebulo Pharmaceuticals, Inc.
ANEB- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001815974
No open-market purchases or sales by Anebulo Pharmaceuticals, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q2 2021 vs. Q1 2021
How the institutions holding Anebulo Pharmaceuticals, Inc. changed between Q1 2021 and Q2 2021.
All holders in Q2 2021All holders in Q1 2021
| Measure | Q1 2021 | Q2 2021 | Change |
|---|---|---|---|
| Holders | 0 | 9 | +9 |
| Shares | 0 | 4.20M | +4.20M |
| Value | $0 | $28.7M | +$28.7M |
New holders (9)
Institutions that held Anebulo Pharmaceuticals, Inc. at the end of Q2 2021 but not at the end of Q1 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| 22NW, LP | 3,343,565 | $22.8M | 6.13% |
| Mangrove Partners | 428,500 | $2.92M | 0.32% |
| Laurion Capital Management LP | 225,000 | $1.55M | 0.02% |
| Ikarian Capital, LLC | 174,811 | $1.20M | 0.22% |
| Boothbay Fund Management, LLC | 19,835 | $135.0K | 0.01% |
| BlackRock Inc. | 7,773 | $53.0K | 0.00% |
| UBS Group AG | 234 | $2.00K | 0.00% |
| Tower Research Capital LLC (TRC) | 158 | $1.00K | 0.00% |
| Wells Fargo & Company | 19 | $0 | 0.00% |
Sold out (0)
Institutions that held Anebulo Pharmaceuticals, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.
None.